FRM
QTTB icon

Fox Run Management’s Q32 Bio QTTB Stock Holding History

Fox Run Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$184K Buy
+22,193
New +$307K 0.02% 870

Other funds holding QTTB

Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fox Run Management's QTTB Position: Q3 2026 in Review

Fox Run Management opened a new position in Q32 Bio (QTTB) in Q3 2026: 22,193 shares worth $184K. The stake represents 0.02% of the portfolio and ranks #870 among its holdings.

61 funds tracked by Wall St. Rank hold QTTB as of Q3 2026.

  • Fox Run Management held 22,193 shares of Q32 Bio worth $184K as of Q3 2026.
  • Q32 Bio was a new Fox Run Management position in Q3 2026.
  • Q32 Bio made up 0.02% of Fox Run Management's portfolio in Q3 2026, its #870 holding.
  • 61 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.